Kristen K. Sheppard
Investor Relations Contact chez CENTESSA PHARMACEUTICALS PLC
Profil
Kristen K.
Sheppard is currently working as a Member at the New Hampshire Bar Association and as SVP-Investor Relations & Communications at Centessa Pharmaceuticals Plc.
Previously, she worked as Senior Vice President-Corporate Communications at Dicerna Pharmaceuticals, Inc. and as Vice President-Investor & Media Relations at NxStage Medical, Inc. She also worked as SVP-Investor Relations & Corporate Communications at Akebia Therapeutics, Inc. She completed her undergraduate degree at the University of New Hampshire and her graduate degree at Suffolk University Law School.
Postes actifs de Kristen K. Sheppard
Sociétés | Poste | Début |
---|---|---|
CENTESSA PHARMACEUTICALS PLC | Investor Relations Contact | 01/06/2022 |
New Hampshire Bar Association | Corporate Officer/Principal | - |
Anciens postes connus de Kristen K. Sheppard
Sociétés | Poste | Fin |
---|---|---|
DICERNA PHARMACEUTICALS, INC. | Investor Relations Contact | 01/06/2022 |
NXSTAGE MEDICAL, INC. | Investor Relations Contact | 19/03/2019 |
AKEBIA THERAPEUTICS, INC. | Investor Relations Contact | - |
Formation de Kristen K. Sheppard
University of New Hampshire | Undergraduate Degree |
Suffolk University Law School | Graduate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 2 |
---|---|
AKEBIA THERAPEUTICS, INC. | Health Technology |
CENTESSA PHARMACEUTICALS PLC | Health Technology |
Entreprise privées | 3 |
---|---|
Dicerna Pharmaceuticals, Inc.
Dicerna Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson, and John J. Rossi in October 2006 and is headquartered in Lexington, MA. | Health Technology |
NxStage Medical, Inc.
NxStage Medical, Inc. Medical SpecialtiesHealth Technology NxStage Medical, Inc. is a medical technology company, which develops, manufactures, and markets products for the treatment of ESRD and acute kidney failure. It operates through the following business segments: System One, In-Center, and Services. The System One segment engages in the sale and rental of the System One and PureFlow SL equipment and the sale of disposable products in the home and critical care markets. The In-Center segment sells blood tubing sets and needles for hemodialysis primarily for the treatment of ESRD patients at dialysis centers and needles for apheresis. The Services segment includes revenues from dialysis services provided to patients at its recently opened NxStage Kidney Care dialysis centers. The company was founded by Jeffrey H. Burbank in December 1998 and is headquartered in Waltham, MA. | Health Technology |
New Hampshire Bar Association |